Cargando…

Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB

Background: The systemic immune-inflammation index (SII) has been identified as a predictor of chemotherapy efficacy for a variety of cancers, and we aimed to determine its ability to predict the response to chemotherapy and its long-term prognosis for patients with cervical squamous cell carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Pingping, Jiang, Yinan, Zheng, Xiaojing, Pan, Baoyue, Xiang, Huiling, Zheng, Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pathology and Oncology Archive
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092215/ https://www.ncbi.nlm.nih.gov/pubmed/35570842 http://dx.doi.org/10.3389/pore.2022.1610294

Ejemplares similares

Pretreatment C-Reactive Protein/Albumin Ratio is Associated With Poor Survival in Patients With 2018 FIGO Stage IB-IIA HPV-Positive Cervical Cancer
por: Jiang, Yinan, et al.
Publicado: (2021)

In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator
por: Chen, Li, et al.
Publicado: (2021)

Prognostic role of pretreatment skeletal muscle index in gastric cancer patients: A meta-analysis
por: He, Xiaohong, et al.
Publicado: (2023)

Predictive role of neostromal CD10 expression in breast cancer patients treated with neoadjuvant chemotherapy
por: Olah, Orsolya, et al.
Publicado: (2023)

A Fifteen‐Gene Classifier to Predict Neoadjuvant Chemotherapy Responses in Patients with Stage IB to IIB Squamous Cervical Cancer
por: Tian, Xun, et al.
Publicado: (2021)

Adjuvant chemotherapy after surgery can improve clinical outcomes for patients with IB2-IIB cervical cancer with neoadjuvant chemotherapy followed by radical surgery
por: Sun, Haiying, et al.
Publicado: (2018)

Thrombospondin 2 is a Functional Predictive and Prognostic Biomarker for Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
por: Lin, Yuxiang, et al.
Publicado: (2022)

Impact of the initial site of metastases on post-recurrence survival for neuroendocrine cervical cancer
por: Pan, Baoyue, et al.
Publicado: (2022)

Pelvic lymph node decidua mimicking metastatic cervical cancer in pregnancy
por: Pfaendler, Krista S, et al.
Publicado: (2022)

Prognostic risk model development and prospective validation among patients with cervical cancer stage IB2 to IIB submitted to neoadjuvant chemotherapy
por: Huang, Kecheng, et al.
Publicado: (2016)

Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival
por: Matsuo, Koji, et al.
Publicado: (2019)

Prognostic value of pretreatment Controlling Nutritional Status score in esophageal cancer: a meta-analysis
por: Lv, Jing, et al.
Publicado: (2023)

The Effect of Neoadjuvant Chemotherapy on Lymph Node Metastasis of FIGO Stage IB1-IIB Cervical Cancer: A Systematic Review and Meta-Analysis
por: Chen, Bingxin, et al.
Publicado: (2020)

Neoadjuvant chemotherapy plus surgery versus concurrent chemoradiotherapy in stage IB2-IIB cervical cancer: A systematic review and meta-analysis
por: Zou, Wen, et al.
Publicado: (2019)

Ubiquitination-Related Molecular Subtypes and a Novel Prognostic Index for Bladder Cancer Patients
por: Cai, Hai, et al.
Publicado: (2021)

Optimal pathological response indicated better long-term outcome among patients with stage IB2 to IIB cervical cancer submitted to neoadjuvant chemotherapy
por: Huang, Kecheng, et al.
Publicado: (2016)

Neoadjuvant chemotherapy followed by surgery has no therapeutic advantages over concurrent chemoradiotherapy in International Federation of Gynecology and Obstetrics stage IB-IIB cervical cancer
por: Lee, Jeongshim, et al.
Publicado: (2016)

Neoadjuvant chemotherapy for locally advanced stage (IB2-IIA2-IIB) cervical carcinoma: Experience of a tertiary center and comprehensive review of the literature
por: Çakır, Caner, et al.
Publicado: (2021)

Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy
por: Tan, Shirong, et al.
Publicado: (2021)

Clinical benefits of oral capecitabine over intravenous 5-fluorouracyl regimen in case of neoadjuvant chemoradiotherapy followed by surgery for locally advanced rectal cancer
por: Paszt, Attila, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy Followed by Radical Surgery versus Radiotherapy (with or without Chemotherapy) in Patients with Stage IB2, IIA, or IIB Cervical Cancer: A Systematic Review and Meta-Analysis
por: Ye, Qingjian, et al.
Publicado: (2020)

Influence of the microbiota on the effectiveness and toxicity of oncological therapies, with a focus on chemotherapy
por: Cazzaniga, Massimiliano, et al.
Publicado: (2023)

Cytokine-induced killer cell treatment is superior to chemotherapy alone in esophageal cancer
por: Sun, Jiayang, et al.
Publicado: (2023)

O-Glycosylating Enzyme GALNT2 Predicts Worse Prognosis in Cervical Cancer
por: Zhou, Lixia, et al.
Publicado: (2022)

Intracystic endometrioid borderline tumor
por: El Hajj, Houssein, et al.
Publicado: (2023)

MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer
por: Ko, Jihoon, et al.
Publicado: (2022)

Serum Tie-1 is a Valuable Marker for Predicting the Progression and Prognosis of Cervical Cancer
por: Bai, Rui, et al.
Publicado: (2021)

High Neutrophil-To-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammation Index (SII) Are Markers of Longer Survival After Metastasectomy of Patients With Liver-Only Metastasis of Rectal Cancer
por: Polk, Nándor, et al.
Publicado: (2022)

Corrigendum: High Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammation Index (SII) are Markers of Longer Survival After Metastasectomy of Patients With Liver-Only Metastasis of Rectal Cancer
por: Polk, Nándor, et al.
Publicado: (2022)

Identification of an Oxidative Stress-Related LncRNA Signature for Predicting Prognosis and Chemotherapy in Patients With Hepatocellular Carcinoma
por: Zhong, Zixuan, et al.
Publicado: (2022)

Decreased Expression of Karyopherin-α 1 is Related to the Malignant Degree of Cervical Cancer and is Critical for the Proliferation of Hela Cells
por: Jiang, Lucen, et al.
Publicado: (2022)

Change in Main Histological Type of Invasive Breast Cancer From Ductal to Lobular Carcinoma by Neoadjuvant Chemotherapy
por: Okubo, Takako, et al.
Publicado: (2023)

The Prognostic Impact of Grading in FIGO IB and IIB Squamous Cell Cervical Carcinomas
por: Brambs, Christine E., et al.
Publicado: (2019)

Late Radiation–Related Toxicities in Patients Treated for Early-Stage Cervical Carcinoma by Surgery and Adjuvant Radiotherapy: A Retrospective Imaging Study
por: Nadova, Katarina, et al.
Publicado: (2021)

Whole-Exome Sequencing Could Distinguish Primary Pulmonary Squamous Cell Carcinoma From Lung Metastases in Individuals With Cervical Squamous Cell Carcinoma
por: Li, Lihong, et al.
Publicado: (2022)

Pathological Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: The Relationship Between Inflammatory Biomarkers and Molecular Subtypes
por: Kaytaz Tekyol, Kübra, et al.
Publicado: (2021)

The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy
por: Yang, Hui, et al.
Publicado: (2021)

Assessing the Correlation of Rate of Pathological Complete Response and Outcome in Post Neoadjuvant Chemotherapy Setting and Molecular Subtypes of Breast Cancer
por: Omair, Ahmad, et al.
Publicado: (2023)

Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
por: Shoji, Tadahiro, et al.
Publicado: (2012)

A Risk Model Based on Immune-Related Genes Predicts Prognosis and Characterizes the Immune Landscape in Esophageal Cancer
por: Xie, Yan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ds6r7dsi6p2b2pdm41hr18etqd